All In MedTech

Device Trial Radar · NCT07582211

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma

Bilevel Positive Airway Pressure (BPAP) for Severe Asthma Exacerbations: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Jul 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Columbia UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Children's Hospital of Philadelphia; Nationwide Children's Hospital; University of Utah; National Heart, Lung, and Blood Institute (NHLBI)
First posted
May 12, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the feasibility of early initiation of bilevel positive airway pressure (BPAP) in the emergency department (ED) for children with severe asthma exacerbations. It will also collect preliminary data on the safety and potential effectiveness of this approach. The main questions it aims to answer are: 1. Can eligible patients be successfully enrolled and complete study procedures across multiple sites? 2. What safety events occur with early BPAP use in this population? 3. How do clinical outcomes (such as symptom improvement and need for intensive care) compare between early BPAP and standard care? Researchers will compare early initiation of BPAP plus standard asthma therapy to standard asthma therapy alone to determine whether early BPAP is a feasible and potentially beneficial treatment strategy. Participants will 1) receive standard asthma therapy with or without early BPAP in the ED, 2) be monitored closely during the ED visit and hospitalization, and 3) have clinical data collected from routine care, including asthma severity scores, treatments, and outcomes. The study will enroll approximately 36 participants (about 12 per site) across three sites over one year to inform a future multicenter randomized controlled trial.

Conditions

  • Pediatric Asthma
  • Acute Asthma
  • BiPAP
  • Non-invasive Positive Pressure Ventilation

Interventions

  • Bilevel positive airway pressure ventilationDevice

    This study involves non-invasive positive pressure ventilation (NIPPV) delivered as bilevel positive airway pressure (BPAP) in children aged 5-17 years presenting to the pediatric emergency department with severe asthma exacerbations. BPAP will be administered using FDA-cleared devices according to their intended use and standard clinical practice. Therapy will be delivered via an appropriately fitted nasal or face mask and managed by trained clinical staff. Ventilator settings will be adjusted at the discretion of the treating clinician, and continuous bronchodilator therapy may be delivered through the BPAP circuit per manufacturer recommendations or site practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of eligible patients who consentTime frame: From screening through randomization, up to 2 hours
  2. Proportion of participants who adhere to the BPAP protocol among all those assigned to the BPAP armTime frame: From randomization through end of 2-hour intervention

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center

    New York, New York

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.